)
)
)
Balancing Global Opportunities and Trade Policy Risks
More than a third of US licensing deals this year have involved assets sourced from China, as accelerating growth in such deals attracts investor attention and regulatory scrutiny. This panel will examine how competition is affecting asset valuations, how deals structures are evolving, and regulatory changes regarding cross-border clinical data security liabilities applicable not just to operators but investors also.